Objectives: To investigate whether serum fibroblast growth factor 21 (FGF21) levels can be used to predict the future development of major adverse cardiovascular events (MACEs). Methods: This study included 253 patients who received subsequent follow-up, and complete data were collected for 234 patients. Independent predictors of MACEs were identified by using the Cox proportional-hazards regression analysis. The prognostic value of FGF21 levels for MACEs was evaluated by Kaplan-Meier survival analysis. Results: Of 229 patients finally enrolled in the analysis, 27/60 without coronary artery disease (CAD) at baseline experienced a MACE, and 132/169 patients with CAD at baseline experienced a MACE. Among patients with CAD at baseline, serum FGF21 levels were significantly higher in patients with MACEs (p < 0.05) than in patients without MACEs. Kaplan-Meier survival analysis showed patients with a higher serum FGF21 had a significantly lower event-free survival (p = 0.001) than those with a lower level. Further Cox proportional-hazards regression analysis, including the traditional risk factors for cardiovascular disease, showed that serum FGF21 was an independent predictor of MACE occurrence. Conclusions: In patients with CAD at baseline, an elevated serum FGF21 level was associated with the development of a MACE in the future.

Keywords:
Fibroblast growth factor 21, Coronary artery disease, Major adverse cardiovascular event
1.
Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
2.
Chen W, Gao R, Liu L, et al: Summary of report on cardiovascular diseases in China 2015. Chin Circ J 2016; 31: 521–528.
3.
Lin X, Xu R, Fang L, et al: Factors influencing low-density lipoprotein cholesterol target achievement in primary care – results from DYSIS China. Int J Cardiol 2016; 222: 51–56.
4.
Ji L, Hu D, Pan C, et al: Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 2013; 126:e11–e22.
5.
Li H, Zhang J, Jia W: Fibroblast growth factor 21:a novel metabolic regulator from pharmacology to physiology. Front Med 2013; 7: 25–30.
6.
Li H, Fang Q, Gao F, et al: Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010; 53: 934–940.
7.
Li H, Dong K, Fang Q, et al: High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol 2013; 58: 557–563.
8.
Shen Y, Ma X, Zhou J, et al: Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 2013; 12: 124.
9.
Shen Y, Zhang X, Pan X, et al: Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death. Cardiovasc Diabetol 2017; 16: 106.
10.
Ong KL, Januszewski AS, O’Connell R, et al: The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 2015; 58: 464–473.
11.
World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. 1. Diagnosis and classification of diabetes mellitus. Geneva, WHO, 1999.
12.
Jian-Gao F: Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhong hua Gan Zang Bing Za Zhi 2010; 18: 163–166.
13.
Yang G, Fan L, Tan J, et al: Smoking in China: findings of the 1996 national prevalence survey. JAMA 1999; 282: 1247–1253.
14.
Barrett-Connor E, Khaw K: Family history of heart attack as an independent predictor of death due to cardiovascular disease. Circulation 1984; 69: 1065–1069.
15.
Li H, Bao Y, Xu A, et al: Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamytransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94: 2151–2156.
16.
Chow WS, Xu A, Woo YC, et al: Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 2454–2459.
17.
Jin L, Lin Z, Xu A: Fibroblast growth factor 21 protects against atherosclerosis via fine-tuning the multiorgan crosstalk. Diabetes Metab J 2016; 40: 22–31.
18.
Berglund ED, Kang L, Lee-Young RS, et al: Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARα and FGF21 transcripts in vivo. Am J Physiol Endocrinol Metab 2010; 299:E607–E614.
19.
Coskun T, Bina HA, Schneider MA, et al: Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149: 6018–6027.
20.
Lü Y, Liu JH, Zhang LK, et al: Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cell. Chin Med J (Engl) 2010; 123: 3417–3421.
21.
Wu X, Qi YF, Chang JR, et al: Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE–/– mice. Heart Vessels 2015; 30: 657–668.
22.
Planavila A, Redondo I, Hondares E, et al: Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 2013; 4: 2019.
23.
Planavila A, Redondo-Angulo I, Ribas F, et al: Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res 2015; 106: 19–31.
24.
Lin Z, Wu Z, Yin X, et al: Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 2010; 29:e15534.
25.
Lenart-Lipińska M, Matyjaszek-Matuszek B, Gernand W, et al: Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract 2013; 101: 194–200.
26.
Woo YC, Xu A, Wang Y, et al: Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 2013; 78: 489–496.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.